Enochian Biosciences, Inc. (ENOB)

Overview

Enochian Biosciences, Inc. is a pre-clinical stage biotechnology firm focused on discovering and developing pharmaceutical and biological treatments aimed at formidable diseases such as HIV, hepatitis B virus (HBV), influenza, coronavirus infections, and cancer. Established in 2017, the company is propelling forward with its cutting-edge research and development efforts from its base in Los Angeles, California. Leveraging strategic partnerships with prestigious institutions like The Scripps Institute, Fred Hutchinson Cancer Research Center, Texas Biomedical Research Institute, University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute, Enochian Biosciences aims to usher in a new era of medical treatments and vaccines. These collaborations are cornerstone to the company’s innovative approach in tackling some of the most challenging viral infections and cancer types.

Products and Services

• ENOB-HV-01: Autologous HIV Curative Treatment

This lead candidate represents a pioneering approach to curing HIV by using a patient’s own cells. It is at the forefront of Enochian Biosciences’ product pipeline, aiming to provide a groundbreaking solution for HIV treatment.

• ENOB-HV-11: Preventative HIV Vaccine

As part of its comprehensive strategy against HIV, ENOB-HV-11 is being developed to offer protection against the virus, preventing infection before it can start. This preventative HIV vaccine could greatly reduce the spread of HIV on a global scale.

• ENOB-HV-12: Therapeutic HIV Vaccine

Alongside its preventative counterpart, this therapeutic HIV vaccine is designed to treat those already infected with HIV, offering them hope for a healthier future by enhancing the body's immune response to the virus.

• ENOB-HB-01: Coopting HBV Polymerase

Targeting the hepatitis B virus, ENOB-HB-01 aims to interrupt the life cycle of HBV, showcasing Enochian Biosciences’ commitment to tackling a broad spectrum of viral diseases beyond HIV.

• ENOB-DC-11: Off The Shelf DC Vaccine for Multiple Solid Tumors

This innovative cancer vaccine strategy looks to combat multiple solid tumors, providing a versatile and potent option for cancer treatment. By leveraging dendritic cells, ENOB-DC-11 could significantly advance cancer immunotherapy.

• ENOB-DC-21: Non-specific Vaccine for Intratumoral Injection

Rounding out Enochian Biosciences' pipeline is ENOB-DC-21, a non-specific vaccine designed for direct injection into tumors. This novel approach represents the company’s foray into localized cancer treatment methods, offering a targeted strategy to combat cancer at the site of the disease.